The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 937 GLP-1 Medications articles
America faces a crisis in unregulated compounded GLP-1 drugs, with FDA reporting 1,150 adverse events including hospitalizations and deaths. Exploiting shortages of semaglutide and tirzepatide, compounders flood the market with untested products, misleading consumers. Now, with the SAFE Drugs Act and FDA crackdowns, it's time to restore safety standards.
As millions using GLP-1 medications like Ozempic® and Wegovy® face post-treatment challenges such as muscle loss and weight regain, ROOT Brands® introduces CRUSH™ and SCULPT™. This cellular-first protocol supports metabolic function and lean muscle preservation without pharmaceuticals. Backed by science, it targets the 'GLP-1 gap' for long-term body composition success.
Roughly half a million Australians are using GLP-1 weight loss drugs like Ozempic and Mounjaro, with some reporting life-changing results while others face side effects. Professor Kelly Lambert from the University of Wollongong shares key insights on what you need to know. This guide covers mechanisms, safety, and practical tips for users.
A groundbreaking 23andMe study published in Nature identifies specific genetic changes in two genes that predict how well patients respond to GLP-1 drugs for weight loss—and whether they'll experience common side effects like nausea or vomiting. Led by Adam Auton, the research offers proof of concept for genetics in GLP-1 therapy. While experts are intrigued, questions remain on clinical impact.
Ozempic users who skip exercise face suboptimal results, according to a new study in Sports Medicine on GLP-1 drugs like Victoza and Saxenda. Among 193 adults, those combining medication with structured workouts saw the best outcomes, while sedentary users fared worst. Meanwhile, one patient's rare blindness side effect highlights ongoing risks.
With 1 in 8 American adults now taking GLP-1 medications for diabetes or weight loss, pharmacists are emerging as crucial allies in ensuring treatment success. According to the American Society of Health-System Pharmacists, these experts help navigate costs, side effects, and lifestyle integration. This guide explores their vital role in maximizing benefits and minimizing risks.
For Canadians without drug coverage, affording Ozempic remains a major hurdle, especially for weight management beyond diabetes. Patients like 77-year-old Anne Welch watch their spouses benefit while rationing hopes on incoming generic semaglutide. With Health Canada reviewing nine submissions, relief may be near—but timelines and costs remain uncertain.
A comprehensive review of over 1,700 clinical trials reveals gastrointestinal adverse events as the most consistent side effects of GLP-1 medications like Ozempic and Wegovy. While these drugs show potential protective effects against infections and dementia, lawsuits over stomach paralysis and vision loss are mounting. Understand the findings and what they mean for your treatment.
Semaglutide injection pens command a higher price than vials primarily due to intricate manufacturing demands in sterile environments and advanced automation, as explained by OneSource Specialty Pharma CEO Neeraj Sharma. With GLP-1 drugs like semaglutide fueling a $34.5 billion market set to double by the mid-2030s, understanding these costs highlights the trade-offs for patient convenience. This guide breaks down the production process and its implications for diabetes and weight management therapies.
